PL2200431T3 - Nowe kompozycje i metody służące leczeniu raka - Google Patents
Nowe kompozycje i metody służące leczeniu rakaInfo
- Publication number
- PL2200431T3 PL2200431T3 PL08830633T PL08830633T PL2200431T3 PL 2200431 T3 PL2200431 T3 PL 2200431T3 PL 08830633 T PL08830633 T PL 08830633T PL 08830633 T PL08830633 T PL 08830633T PL 2200431 T3 PL2200431 T3 PL 2200431T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- cancer treatment
- novel compositions
- compositions
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97114407P | 2007-09-10 | 2007-09-10 | |
US1337207P | 2007-12-13 | 2007-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2200431T3 true PL2200431T3 (pl) | 2017-01-31 |
Family
ID=40452461
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08830633T PL2200431T3 (pl) | 2007-09-10 | 2008-09-10 | Nowe kompozycje i metody służące leczeniu raka |
PL16156278T PL3067054T3 (pl) | 2007-09-10 | 2008-09-10 | Nowe kompozycje i sposoby leczenia nowotworów |
PL08830619.6T PL2190429T3 (pl) | 2007-09-10 | 2008-09-10 | Nowa grupa inhibitorów szlaku białka stat3 oraz inhibitorów szlaku nowotworowych komórek macierzystych |
PL08830471T PL2194987T3 (pl) | 2007-09-10 | 2008-09-10 | Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16156278T PL3067054T3 (pl) | 2007-09-10 | 2008-09-10 | Nowe kompozycje i sposoby leczenia nowotworów |
PL08830619.6T PL2190429T3 (pl) | 2007-09-10 | 2008-09-10 | Nowa grupa inhibitorów szlaku białka stat3 oraz inhibitorów szlaku nowotworowych komórek macierzystych |
PL08830471T PL2194987T3 (pl) | 2007-09-10 | 2008-09-10 | Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych |
Country Status (15)
Country | Link |
---|---|
US (12) | US9745278B2 (ja) |
EP (6) | EP3067054B1 (ja) |
JP (16) | JP5872160B2 (ja) |
CN (6) | CN101854930B (ja) |
CA (4) | CA2911990C (ja) |
CY (3) | CY1117604T1 (ja) |
DK (4) | DK2200431T3 (ja) |
ES (3) | ES2569215T3 (ja) |
HK (3) | HK1148942A1 (ja) |
HR (3) | HRP20160430T1 (ja) |
HU (3) | HUE027657T2 (ja) |
PL (4) | PL2200431T3 (ja) |
PT (2) | PT2200431T (ja) |
SI (3) | SI2190429T1 (ja) |
WO (3) | WO2009036059A2 (ja) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
CN101854930B (zh) * | 2007-09-10 | 2016-05-04 | 北京强新生物科技有限公司 | 一类新的stat3通路抑制剂和癌干细胞通路抑制剂 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
US20130331294A1 (en) | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
EP2310011B1 (en) | 2008-06-17 | 2013-07-24 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
UA103492C2 (ru) | 2008-07-08 | 2013-10-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) |
AU2009279771B2 (en) | 2008-08-04 | 2015-05-14 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
CA2745265A1 (en) * | 2008-12-01 | 2010-06-10 | James Turkson | Drug composition cytotoxic for pancreatic cancer cells |
KR20220143154A (ko) | 2009-04-06 | 2022-10-24 | 와이어쓰 엘엘씨 | 네라티닙을 이용한 유방암의 치료법 |
CN101897979B (zh) * | 2009-05-27 | 2012-08-22 | 上海市计划生育科学研究所 | 治疗前列腺疾病的靶向药物 |
WO2011069141A2 (en) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
CA2785679C (en) | 2009-12-28 | 2017-12-12 | General Incorporated Association Pharma Valley Project Supporting Organization | 1,3,4-oxadiazole-2-carboxamide compound |
US20110275577A1 (en) * | 2010-01-08 | 2011-11-10 | Moleculin, Llc | Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs |
KR101821343B1 (ko) | 2010-03-01 | 2018-01-23 | 타우 쎄라퓨틱스 엘엘씨 | 암 진단 및 영상화 |
DK3108750T3 (en) * | 2010-03-19 | 2018-10-22 | 1Globe Biomedical Co Ltd | NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS |
CN107375260B (zh) | 2010-03-19 | 2023-10-24 | 北京强新生物科技有限公司 | 靶向癌症干细胞的新的化合物和组合物 |
RU2591823C2 (ru) * | 2010-03-19 | 2016-07-20 | Бостон Байомедикал, Инк. | Новые способы направленного воздействия на раковые стволовые клетки |
AU2015218436B9 (en) * | 2010-03-19 | 2017-03-09 | Boston Biomedical, Inc. | Novel Methods For Targeting Cancer Stem Cells |
WO2011130677A1 (en) * | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibitors of cancer stem cells |
US20110301194A1 (en) * | 2010-06-02 | 2011-12-08 | Arqule, Inc. | Method for Determining Treatment Efficacy |
US8871802B2 (en) | 2010-08-24 | 2014-10-28 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Naphthoquinones for disease therapies |
EP2617435A4 (en) * | 2010-09-16 | 2014-03-12 | Univ Osaka | THERAPEUTICS AND PROPHYLACTIC AGENTS FOR COMPOSITIONS OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES, ALLERGIC DISEASES AND ORGAN TRANSPLANTS |
JP2013543011A (ja) * | 2010-11-22 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 癌の治療法 |
CN103260647A (zh) * | 2010-11-30 | 2013-08-21 | 伦敦健康科学中心研究公司 | 用于治疗心脏病的egfr拮抗剂 |
WO2012078982A2 (en) * | 2010-12-09 | 2012-06-14 | The Ohio State University | Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells |
WO2012119265A1 (en) * | 2011-03-04 | 2012-09-13 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
KR20120130658A (ko) * | 2011-05-23 | 2012-12-03 | 주식회사 파멥신 | 펩타이드가 융합된 이중표적항체 및 그 용도 |
EP3251671A1 (en) * | 2011-06-06 | 2017-12-06 | Akebia Therapeutics Inc. | Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
JP2014526475A (ja) * | 2011-09-12 | 2014-10-06 | タウ セラピューティクス エルエルシー | がん幹細胞を含む幹細胞の増殖、進展、または分化の阻害のためのHs.459642ユニジーンクラスター産物のアンタゴニスト |
EP2776586B1 (en) * | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
US20150164794A1 (en) * | 2012-02-17 | 2015-06-18 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals, Co., Ltd. | METHOD FOR PREPARING AQUEOUS NANOPARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
CN103705926A (zh) * | 2012-10-08 | 2014-04-09 | 贾力 | 预防原发性肿瘤在手术切除后再转移的药用组合物 |
DE102013003107A1 (de) | 2013-02-25 | 2014-09-11 | Thomas Rühl | Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
EP2983790A2 (en) * | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
US10745489B2 (en) | 2013-04-29 | 2020-08-18 | Ogd2 Pharma | Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer |
AU2014261788B2 (en) * | 2013-04-29 | 2019-07-11 | Nantes Université | Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells Cancer |
SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9795595B2 (en) | 2014-01-27 | 2017-10-24 | Boston Biomedical, Inc. | Methods for treating cancer |
EP3102036A4 (en) * | 2014-02-07 | 2017-09-20 | Boston Biomedical, Inc. | 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof |
WO2015120436A2 (en) | 2014-02-10 | 2015-08-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Stat3 phosphorylation during graft-versus-host disease |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6894236B2 (ja) * | 2014-03-26 | 2021-06-30 | デノボ バイオファーマ エルエルシー | 免疫刺激活性を有するレトロウイルスベクター |
WO2015164870A1 (en) | 2014-04-25 | 2015-10-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gamma-aa-peptide stat3/dna inhibitors and methods of use |
US20170266182A1 (en) * | 2014-05-09 | 2017-09-21 | The Brigham And Women's Hospital, Inc. | Treatment of IgG-Immune Complex-Mediated Organ Damage |
ES2792851T3 (es) * | 2014-06-09 | 2020-11-12 | Kyoto Pharma Ind | Derivados de naftofurano para uso como agentes antineoplásicos |
WO2016010879A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
CN107635991B (zh) | 2015-01-08 | 2021-01-01 | 美国政府健康及人类服务部 | 作为tdp2的抑制剂的呋喃并喹啉二酮 |
WO2016157052A1 (en) | 2015-03-27 | 2016-10-06 | Boston Biomedical, Inc. | Water-soluble prodrugs |
CN104693279A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 关于信号传导及转录激活因子抑制多肽及其应用 |
CN104693280A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 信号传导及转录激活因子抑制多肽及其应用 |
CN104725480A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种信号传导及转录激活因子抑制多肽及其应用 |
MX2017013360A (es) | 2015-04-17 | 2018-08-01 | Boston Biomedical Inc | Métodos para tratar el cáncer. |
TW201713328A (zh) | 2015-04-17 | 2017-04-16 | 波士頓生醫公司 | 治療癌症之方法 |
EP3283070A1 (en) * | 2015-04-17 | 2018-02-21 | Boston Biomedical, Inc. | Methods for treating cancer |
KR20170141716A (ko) * | 2015-04-27 | 2017-12-26 | 보스톤 바이오메디칼, 인크. | Stat3 경로 저해제 및 카이나제 저해제를 사용하여 암을 치료하는 방법 |
EA201792509A1 (ru) * | 2015-05-14 | 2018-05-31 | НУКАНА ПиЭлСи | Лечение рака |
US10881664B2 (en) * | 2015-05-15 | 2021-01-05 | Novartis Ag | Methods for treating EGFR mutant cancers |
JP2018521979A (ja) * | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル, インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
US10329267B2 (en) | 2015-07-17 | 2019-06-25 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
WO2017023866A1 (en) * | 2015-07-31 | 2017-02-09 | Boston Biomedical, Inc. | Method of targeting stat3 and other non-druggable proteins |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
KR20180063075A (ko) | 2015-10-05 | 2018-06-11 | 뉴카나 피엘씨 | 조합 요법 |
CA3010786A1 (en) * | 2016-01-07 | 2017-07-13 | Virginia Commonwealth University | A method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp) |
CA3011800A1 (en) | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
US11434229B2 (en) * | 2016-03-01 | 2022-09-06 | Academia Sinica | 4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
JP2017171640A (ja) * | 2016-03-25 | 2017-09-28 | 学校法人兵庫医科大学 | 癌の治療システム |
JP6936214B2 (ja) | 2016-03-25 | 2021-09-15 | 大日本住友製薬株式会社 | 2−アルキルカルボニルナフト[2,3−b]フラン−4,9−ジオンの関連物質の製造方法、及びその関連物質 |
CN105906595A (zh) * | 2016-04-23 | 2016-08-31 | 陈斌 | 丙酸倍氯米松的药物组合物及其在生物医药中的应用 |
CN105837541A (zh) * | 2016-04-23 | 2016-08-10 | 何淑琼 | 磷酸苯丙哌林的药物组合物及其在生物医药中的应用 |
GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP2019519573A (ja) | 2016-06-28 | 2019-07-11 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
CN106380456B (zh) * | 2016-08-29 | 2019-03-26 | 中南大学 | 一种合成苯并呋喃萘醌衍生物的方法 |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
US20190375723A1 (en) | 2016-11-22 | 2019-12-12 | Boston Biomedical, Inc. | New Naphtho[2,3-B]Furan Derivatives |
US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
KR20190089191A (ko) * | 2016-11-30 | 2019-07-30 | 타임, 인크. | 티로신 유도체 및 이들을 포함하는 조성물 |
JP2020505343A (ja) * | 2017-01-22 | 2020-02-20 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | ピリミジンタイプの代謝拮抗薬と組み合わせたegfr/her2阻害剤の使用 |
WO2018183908A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
JP2020525758A (ja) * | 2017-06-04 | 2020-08-27 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズRappaport Family Institute for Research in the Medical Sciences | 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット |
EP3654841B1 (en) * | 2017-07-20 | 2024-02-07 | Board Of Supervisors Of Louisiana State University | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients |
US20200207782A1 (en) | 2017-09-22 | 2020-07-02 | Sumitomo Dainippon Pharma Co., Ltd | Chemically activated water-soluble prodrug |
KR20240065190A (ko) * | 2017-11-16 | 2024-05-14 | 티르노보 리미티드 | 암 치료용 irs/stat3 이중 조절제 및 항 pd-1/pd-l1 항체의 조합물 |
EP3501511A1 (en) * | 2017-12-22 | 2019-06-26 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Means for preventing and treating brain metastasis |
CN111542598B (zh) * | 2017-12-28 | 2024-07-30 | 株式会社钟化 | 多能干细胞聚集抑制剂 |
CN107973788B (zh) * | 2018-01-09 | 2021-07-09 | 沈阳药科大学 | Bbi608衍生物及其制备与用途 |
ES2941771T3 (es) | 2018-03-20 | 2023-05-25 | Sumitomo Pharma Co Ltd | Derivados de dihidrocromeno |
ES2911428T3 (es) * | 2018-04-19 | 2022-05-19 | Tvardi Therapeutics Inc | Inhibidores de STAT3 |
WO2019232214A1 (en) | 2018-05-31 | 2019-12-05 | Boston Biomedical, Inc. | Methods of using napabucasin |
CN112703001A (zh) * | 2018-09-18 | 2021-04-23 | 株式会社益力多本社 | 使用喹啉羧酰胺衍生物的癌症联用疗法 |
EP3865130A4 (en) | 2018-10-12 | 2022-07-20 | 1Globe Biomedical Co., Ltd. | NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT CANCER |
CN109846888A (zh) * | 2018-10-31 | 2019-06-07 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物 |
CN109966297A (zh) * | 2018-10-31 | 2019-07-05 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物 |
CN109172563A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物 |
CN109288846A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物 |
CN109200052A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物 |
CN109288845A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法 |
CN109288847A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物 |
CN109331004A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物 |
CN109223758A (zh) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴类stat3抑制剂联合用药物组合物 |
CN109200044A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物 |
CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
CA3136230A1 (en) * | 2019-04-09 | 2020-10-15 | Generos Biopharma Ltd. | Pharmaceutical combination of pimozide and methotrexate and use thereof |
US11564913B2 (en) * | 2019-05-03 | 2023-01-31 | Children's Hospital Medical Center | Compositions and methods for treating cancer |
CN110218198B (zh) * | 2019-05-22 | 2022-06-28 | 广州中医药大学(广州中医药研究院) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 |
US20220315551A1 (en) * | 2019-06-14 | 2022-10-06 | Sumitomo Dainippon Pharma Co., Ltd. | 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR |
JP7287929B2 (ja) * | 2019-09-25 | 2023-06-06 | 住友ファーマ株式会社 | ジヒドロクロメン誘導体を含有する医薬 |
US20220401436A1 (en) * | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
AU2020386436A1 (en) * | 2019-11-20 | 2022-05-26 | Yale University | Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury |
CN115297850A (zh) * | 2019-12-05 | 2022-11-04 | 得克萨斯州大学系统董事会 | 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗 |
WO2021185234A1 (zh) * | 2020-03-16 | 2021-09-23 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 |
JP2023525767A (ja) * | 2020-05-11 | 2023-06-19 | パーデュー・リサーチ・ファウンデーション | 連続フロー条件下でのロムスチンのスケールアップ合成 |
CN114286684B (zh) * | 2020-07-27 | 2024-01-05 | 华中科技大学 | 与stat3相关的疾病的预防和/或治疗 |
WO2022216930A1 (en) * | 2021-04-08 | 2022-10-13 | Virginia Commonwealth University | Novel mda-9 antagonist with anti-metastatic potential |
CN114591306B (zh) * | 2022-03-03 | 2024-03-01 | 陕西中医药大学 | 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2472133A (en) * | 1947-03-20 | 1949-06-07 | Du Pont | Thiophanthraquinone derivatives |
SU1049490A1 (ru) | 1982-05-18 | 1983-10-23 | Ордена Трудового Красного Знамени Институт Химии Ан Мсср | (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции |
JPS616149A (ja) | 1984-06-20 | 1986-01-11 | Mitsubishi Electric Corp | 無機絶縁体の製法 |
JPS63196576A (ja) * | 1987-02-10 | 1988-08-15 | Tetsuo Ikegawa | フラルナフトキノン誘導体と制癌剤及びその製造方法 |
EP0309926A3 (de) | 1987-09-29 | 1990-12-05 | Siemens Aktiengesellschaft | Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik |
JPH01121284A (ja) | 1987-11-06 | 1989-05-12 | Eisai Co Ltd | トコフェロール n,n−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩 |
EP0402192A1 (fr) | 1989-05-31 | 1990-12-12 | BODET, Jean Augustin | Article en carton ou matière analogue et procédé de fabrication |
JPH04139177A (ja) * | 1989-12-28 | 1992-05-13 | Dainippon Ink & Chem Inc | フラルベンゾキノン誘導体及びその製造方法並びに制癌剤 |
JP2942015B2 (ja) * | 1990-07-10 | 1999-08-30 | キヤノン株式会社 | 電子写真感光体およびそれを用いた電子写真装置 |
EP0757292B1 (en) * | 1990-07-10 | 1999-12-22 | Canon Kabushiki Kaisha | Electrophotographic photosensitive member |
TW252136B (ja) * | 1992-10-08 | 1995-07-21 | Ciba Geigy | |
JP3598168B2 (ja) | 1996-03-18 | 2004-12-08 | 独立行政法人 科学技術振興機構 | 抗ウイルス剤 |
JPH1121284A (ja) | 1997-06-30 | 1999-01-26 | Kotobuki:Kk | フラノナフトキノン誘導体及びこれを含有する医薬 |
JPH1165141A (ja) * | 1997-08-11 | 1999-03-05 | Canon Inc | 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置 |
US6174913B1 (en) * | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
WO2000044774A2 (en) | 1999-01-27 | 2000-08-03 | The University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
CA2366787C (en) | 1999-04-01 | 2013-03-12 | Inex Pharmaceuticals Corp. | Compositions and methods for treating lymphoma |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
TR200200263T2 (tr) | 1999-08-02 | 2004-12-21 | F.Hoffmann-La Roche Ag | Yeni seçiçi retinoid agonistleri |
JP2001097860A (ja) | 1999-09-29 | 2001-04-10 | Japan Science & Technology Corp | 抗薬剤耐性菌剤と抗クラミジア剤 |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
WO2002078617A2 (en) * | 2001-03-28 | 2002-10-10 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
GB0117696D0 (en) | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
WO2003045357A1 (en) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
EP1990055A3 (en) | 2001-11-29 | 2011-11-16 | Therakos, Inc. | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells |
CA2478338A1 (en) * | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
US7462596B2 (en) * | 2002-03-15 | 2008-12-09 | Natimmune A/S | Pharmaceutical compositions comprising mannose binding lectin |
WO2004024145A1 (en) | 2002-09-10 | 2004-03-25 | Dabur Research Foundation | Anti-cancer activity of carvedilol and its isomers |
WO2004026253A2 (en) * | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Novel lapacho compounds and methods of use thereof |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
TWI323662B (en) | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
IS6633A (is) | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Samsetningar af fínasteríð töflum |
AU2004256425A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2005016946A2 (en) | 2003-08-13 | 2005-02-24 | University Of South Florida | Platinum complexes for the treatment of tumors |
US20050049207A1 (en) | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and preventing cancer |
WO2005033048A2 (en) * | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Wnt pathway antagonists |
CN1913915B (zh) | 2003-12-02 | 2010-12-01 | 克里夫兰临床基金会 | 使用鞭毛蛋白防止辐射的方法 |
PT1701941E (pt) * | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
DE10359828A1 (de) * | 2003-12-12 | 2005-07-28 | Zoser B. Dr.Rer.Nat. Salama | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe |
EP1748772A2 (en) * | 2004-04-09 | 2007-02-07 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
JP2004224802A (ja) * | 2004-04-21 | 2004-08-12 | Japan Science & Technology Agency | 抗菌剤 |
WO2006014359A2 (en) * | 2004-07-02 | 2006-02-09 | Icos Corporation | Compounds useful for inhibiting chk1 |
US20070249636A1 (en) * | 2004-08-18 | 2007-10-25 | Astrazeneca Ab | Selected Fused Heterocyclics and Uses Thereof |
BRPI0517652A (pt) * | 2004-11-08 | 2008-10-14 | Baxter Healthcare Sa | composições farmacêuticas nanoparticuladas de inibidores de tubulina, métodos para as suas preparações e respectivos usos |
EP1885352A2 (en) * | 2004-11-24 | 2008-02-13 | Novartis AG | Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
US7807662B2 (en) | 2004-12-23 | 2010-10-05 | University Of South Florida | Platinum IV complex inhibitor |
JP2008535785A (ja) * | 2005-02-25 | 2008-09-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Stat3の小分子阻害剤およびその使用 |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
JP2006290871A (ja) * | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
WO2006126505A1 (ja) | 2005-05-26 | 2006-11-30 | The University Of Tokyo | Stat機能阻害剤およびその応用 |
WO2007013946A2 (en) * | 2005-07-20 | 2007-02-01 | University Of South Florida | Method of predicting responsiveness to chemotherapy and selecting treatments |
CA2625219A1 (en) | 2005-10-13 | 2007-04-19 | Orchid Research Laboratories Limited | Heterocyclic compounds as pstat3/il-6 inhibitors |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
JP2007145680A (ja) | 2005-11-30 | 2007-06-14 | Idemitsu Kosan Co Ltd | 水素発生材料および水素発生方法 |
BRPI0620624A2 (pt) * | 2005-12-24 | 2011-11-16 | Biotica Tech Ltd | análogo de 21-deóximacbecina ou um sal farmaceuticamente aceitável do mesmo, método para a produção do mesmo, composição farmacêutica, cepas hospedeira e engenheirada, e, uso das mesmas |
US20090012075A1 (en) * | 2006-01-12 | 2009-01-08 | Miller Thomas A | Fluorinated Arylamide Derivatives |
JP5528708B2 (ja) * | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | 安定な製剤ならびにそれらを調製および使用する方法 |
US20070243192A1 (en) * | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
US20090286772A1 (en) * | 2006-02-24 | 2009-11-19 | Anh Chau | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles |
WO2007115269A2 (en) * | 2006-03-31 | 2007-10-11 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
US20070238770A1 (en) | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
WO2008094321A2 (en) | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
WO2008077062A2 (en) | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression of stat3 reactivation after src kinase inhibition to treat cancer |
JP4077863B1 (ja) * | 2007-05-31 | 2008-04-23 | タヒボジャパン株式会社 | 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法 |
CN101854930B (zh) * | 2007-09-10 | 2016-05-04 | 北京强新生物科技有限公司 | 一类新的stat3通路抑制剂和癌干细胞通路抑制剂 |
WO2009060282A2 (en) | 2007-11-06 | 2009-05-14 | Orchid Research Laboratories Limited | Stilbene derivatives as pstat3/il-6 inhibitors |
CN107375260B (zh) | 2010-03-19 | 2023-10-24 | 北京强新生物科技有限公司 | 靶向癌症干细胞的新的化合物和组合物 |
AU2015218436B9 (en) | 2010-03-19 | 2017-03-09 | Boston Biomedical, Inc. | Novel Methods For Targeting Cancer Stem Cells |
RU2591823C2 (ru) | 2010-03-19 | 2016-07-20 | Бостон Байомедикал, Инк. | Новые способы направленного воздействия на раковые стволовые клетки |
DK3108750T3 (en) | 2010-03-19 | 2018-10-22 | 1Globe Biomedical Co Ltd | NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS |
WO2012119265A1 (en) | 2011-03-04 | 2012-09-13 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
WO2013166618A1 (en) | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
EP3283070A1 (en) | 2015-04-17 | 2018-02-21 | Boston Biomedical, Inc. | Methods for treating cancer |
MX2017013360A (es) | 2015-04-17 | 2018-08-01 | Boston Biomedical Inc | Métodos para tratar el cáncer. |
TW201713328A (zh) | 2015-04-17 | 2017-04-16 | 波士頓生醫公司 | 治療癌症之方法 |
KR20170141716A (ko) | 2015-04-27 | 2017-12-26 | 보스톤 바이오메디칼, 인크. | Stat3 경로 저해제 및 카이나제 저해제를 사용하여 암을 치료하는 방법 |
JP2018521979A (ja) | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル, インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
CA3011800A1 (en) | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
-
2008
- 2008-09-10 CN CN200880115250.2A patent/CN101854930B/zh active Active
- 2008-09-10 EP EP16156278.0A patent/EP3067054B1/en active Active
- 2008-09-10 JP JP2010524251A patent/JP5872160B2/ja not_active Expired - Fee Related
- 2008-09-10 CA CA2911990A patent/CA2911990C/en not_active Expired - Fee Related
- 2008-09-10 HU HUE08830471A patent/HUE027657T2/en unknown
- 2008-09-10 CN CN201610134121.4A patent/CN105963289B/zh active Active
- 2008-09-10 JP JP2010524249A patent/JP5701603B2/ja not_active Expired - Fee Related
- 2008-09-10 CA CA2736564A patent/CA2736564A1/en not_active Abandoned
- 2008-09-10 DK DK08830633.7T patent/DK2200431T3/en active
- 2008-09-10 EP EP08830619.6A patent/EP2190429B1/en active Active
- 2008-09-10 CN CN200880115249.XA patent/CN101854802B/zh active Active
- 2008-09-10 SI SI200831606A patent/SI2190429T1/sl unknown
- 2008-09-10 US US12/677,513 patent/US9745278B2/en active Active
- 2008-09-10 HU HUE08830633A patent/HUE029111T2/en unknown
- 2008-09-10 CA CA2736532A patent/CA2736532C/en not_active Expired - Fee Related
- 2008-09-10 PL PL08830633T patent/PL2200431T3/pl unknown
- 2008-09-10 DK DK08830619.6T patent/DK2190429T3/en active
- 2008-09-10 EP EP08830471.2A patent/EP2194987B1/en active Active
- 2008-09-10 CN CN201410583457.XA patent/CN104586832B/zh active Active
- 2008-09-10 EP EP16156290.5A patent/EP3058941B1/en active Active
- 2008-09-10 ES ES08830619.6T patent/ES2569215T3/es active Active
- 2008-09-10 CN CN201310052882.1A patent/CN103288787B/zh active Active
- 2008-09-10 SI SI200831655A patent/SI2200431T1/sl unknown
- 2008-09-10 DK DK16156335.8T patent/DK3050566T3/en active
- 2008-09-10 US US12/677,511 patent/US8877803B2/en not_active Expired - Fee Related
- 2008-09-10 PL PL16156278T patent/PL3067054T3/pl unknown
- 2008-09-10 ES ES08830633.7T patent/ES2584904T3/es active Active
- 2008-09-10 WO PCT/US2008/075848 patent/WO2009036059A2/en active Application Filing
- 2008-09-10 PT PT88306337T patent/PT2200431T/pt unknown
- 2008-09-10 SI SI200831626A patent/SI2194987T1/sl unknown
- 2008-09-10 PT PT88304712T patent/PT2194987T/pt unknown
- 2008-09-10 JP JP2010524243A patent/JP5688840B2/ja not_active Expired - Fee Related
- 2008-09-10 DK DK08830471.2T patent/DK2194987T3/en active
- 2008-09-10 ES ES08830471.2T patent/ES2583010T3/es active Active
- 2008-09-10 EP EP16156335.8A patent/EP3050566B1/en active Active
- 2008-09-10 CA CA2736563A patent/CA2736563C/en not_active Expired - Fee Related
- 2008-09-10 PL PL08830619.6T patent/PL2190429T3/pl unknown
- 2008-09-10 PL PL08830471T patent/PL2194987T3/pl unknown
- 2008-09-10 CN CN2008801152470A patent/CN101854937B/zh active Active
- 2008-09-10 WO PCT/US2008/075906 patent/WO2009036101A1/en active Application Filing
- 2008-09-10 US US12/677,516 patent/US9732055B2/en active Active
- 2008-09-10 HU HUE08830619A patent/HUE027443T2/en unknown
- 2008-09-10 EP EP08830633.7A patent/EP2200431B1/en active Active
- 2008-09-10 WO PCT/US2008/075903 patent/WO2009036099A1/en active Application Filing
-
2011
- 2011-03-28 HK HK11103100.8A patent/HK1148942A1/zh unknown
- 2011-03-28 HK HK11103107.1A patent/HK1148906A1/xx unknown
- 2011-03-28 HK HK11103106.2A patent/HK1148943A1/xx unknown
-
2014
- 2014-09-02 JP JP2014177915A patent/JP5938072B2/ja not_active Expired - Fee Related
- 2014-09-02 JP JP2014177908A patent/JP5925849B2/ja not_active Expired - Fee Related
- 2014-09-29 US US14/499,299 patent/US9834532B2/en active Active
- 2014-11-17 JP JP2014232396A patent/JP6106149B2/ja not_active Expired - Fee Related
- 2014-11-17 JP JP2014232397A patent/JP2015034179A/ja not_active Withdrawn
-
2015
- 2015-11-26 JP JP2015230291A patent/JP6358659B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-13 JP JP2016004076A patent/JP6347795B2/ja not_active Expired - Fee Related
- 2016-02-01 JP JP2016016973A patent/JP6346628B2/ja not_active Expired - Fee Related
- 2016-04-21 HR HRP20160430TT patent/HRP20160430T1/hr unknown
- 2016-05-11 CY CY20161100393T patent/CY1117604T1/el unknown
- 2016-05-16 JP JP2016097607A patent/JP2016147906A/ja not_active Withdrawn
- 2016-06-07 HR HRP20160625TT patent/HRP20160625T1/hr unknown
- 2016-07-19 CY CY20161100701T patent/CY1118476T1/el unknown
- 2016-07-26 CY CY20161100733T patent/CY1117833T1/el unknown
- 2016-07-26 HR HRP20160949TT patent/HRP20160949T1/hr unknown
-
2017
- 2017-02-10 US US15/429,939 patent/US20170197932A1/en not_active Abandoned
- 2017-07-11 US US15/647,054 patent/US20180030021A1/en not_active Abandoned
- 2017-07-20 US US15/655,366 patent/US20180030022A1/en not_active Abandoned
- 2017-12-19 JP JP2017242778A patent/JP2018076349A/ja not_active Withdrawn
-
2018
- 2018-05-29 JP JP2018102234A patent/JP2018131464A/ja not_active Withdrawn
- 2018-10-16 US US16/161,413 patent/US10851075B2/en active Active
- 2018-12-31 US US16/236,948 patent/US20200039948A1/en not_active Abandoned
-
2019
- 2019-01-14 US US16/246,829 patent/US10377731B2/en not_active Expired - Fee Related
- 2019-02-21 JP JP2019029436A patent/JP2019073560A/ja active Pending
-
2020
- 2020-05-14 JP JP2020085065A patent/JP2020117547A/ja active Pending
- 2020-05-15 US US16/875,479 patent/US20210024482A1/en not_active Abandoned
- 2020-05-26 JP JP2020091326A patent/JP2020143135A/ja active Pending
- 2020-10-09 US US17/066,885 patent/US20210115006A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160949T1 (hr) | Novi sastavi i metode za liječenje karcinoma | |
IL257681A (en) | Methods and compositions for the treatment of cancer | |
SI2173379T1 (sl) | Sestavki in postopki za zdravljenje in diagnosticiranje raka | |
HK1140944A1 (en) | Methods and compositions for treating recurrent cancer | |
IL218987A0 (en) | Methods and compositions for treating cancer | |
HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
EP2125887A4 (en) | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
HK1137158A1 (en) | Formulations for cancer treatment | |
EP2155249A4 (en) | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER | |
EP2340027A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
EP2049151A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
EP2419136A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
HRP20130642T1 (en) | Methods and compositions for treating cancers | |
EP2176406A4 (en) | COMPOSITIONS AND METHOD FOR CANCER TREATMENT | |
EP2391363A4 (en) | COMPOSITIONS AND METHOD FOR CANCER TREATMENT | |
EP2150270A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
IL204945A0 (en) | Compositions and methods for inhibiting tumor progression | |
EP2437738A4 (en) | METHOD AND COMPOSITIONS FOR CANCER TREATMENT | |
EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
GB0707556D0 (en) | Treatment for cancer | |
EP2252298A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF LUNG CANCER | |
HUE054409T2 (hu) | Új kompozíciók és eljárások rák kezelésére | |
SI3067054T1 (sl) | Novi sestavki in postopki za zdravljenje raka | |
EP2068629A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
GB0700493D0 (en) | Cancer treatment |